On December 30, 2022 PharmaMar (MSE: PHM) has reported the initiation of a new Phase I clinical trial with PM534, a novel marine-derived anti-tumor compound resulting from the Company’s research program for the treatment of solid tumors (Press release, PharmaMar, DEC 30, 2022, View Source [SID1234625687]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

PM534 has been tested in the laboratory, both in cell cultures (in vitro) and in animals (in vivo). In both cases, PM534 showed relevant antitumor activity in a wide variety of tumor types, including those with resistance to other chemotherapies.

The objectives of this first human clinical trial are to find the recommended dose and, in turn, to evaluate the safety and efficacy profile.

The trial will be conducted in patients with advanced solid tumors who will be administered the drug intravenously.